Pfizer Launches On-Line Site for Tracking Development Compounds Across its Largest-Ever Pipeline
New Site Part of Pfizer Commitment to Enhanced Transparency for Investors As Well As Scientific and Medical Communities
NEW YORK, Dec. 20 /PRNewswire-FirstCall/ -- Pfizer announced today it is launching an on-line site where the progress of compounds in its research and development pipeline will be made available to investors, plus the scientific and medical communities, and regularly updated.
The new site provides details of Pfizer's largest-ever pipeline and innovative research in cancer, heart disease, diabetes, neurological and infectious diseases, and many other disease areas. The site includes clinical programs from Phase I compounds to late-stage medicines under regulatory review plus recently-approved products. It is now available at http://www.pfizer.com/pipeline .
"Today's posting will provide investors as well as the scientific and medical communities with more detail on our pipeline than ever before, as well as the ability to see updates on our progress," said Dr. John LaMattina, President of Pfizer Global Research and Development. "We have the largest and most diverse pipeline in our history. One of our most important business priorities is bringing these compounds forward so that they reach the patients who need them and drive our long-term growth. We have set specific and realistic goals for introducing a steady stream of new products in the years ahead -- four internally developed products by 2011 plus two externally acquired products by 2010 -- and we look forward to reporting on our progress."
He continued, "We have more experimental medicines and clinical programs than ever before in our history, with potential breakthrough therapies across many major therapeutic areas. By making this information available on-line, we will give investors, physicians and patients deeper insights into our goals, the scope and progress of clinical trials for individual compounds, and our overall mission to fight and cure disease."
Today's launch follows the company's commitment, made to analysts and investors at its November 30 R&D briefing, to make available pipeline details before the end of this year. At that briefing the company described 30 research programs, with more than half highlighted for the first time. Pfizer's pipeline has nearly 250 preclinical and clinical programs, including 169 new molecular entities.
Descriptions of Pfizer's eleven major therapeutic areas and 63 diseases that are at the center of its research efforts are also provided on the new website, which will be updated twice a year.
DISCLOSURE NOTICE: The information contained in this release is as of December 20, 2006. The Company assumes no obligation to update any forward- looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about the introduction of new products that involves substantial risks and uncertainties. A description of these risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005 and in its reports on Forms 10-Q and 8-K.
SOURCE Pfizer Inc